Neuralink Begins Human Trials with Ambitious Goals Amid Scrutiny

Elon Musk's Neuralink has initiated human testing of its brain chip, aiming to treat neurological conditions and eventually achieve human-AI symbiosis, despite facing ethical and safety concerns.

Elon Musk's company Neuralink has started implanting its brain chips in humans, with the first human patient implanted in January 2024, aiming to treat conditions such as paralysis and blindness.
The U.S. Food and Drug Administration (FDA) approved Neuralink for human trials in 2023, after initially rejecting the company's bid due to concerns over potential risks.
Neuralink faces criticism for its animal testing practices and missed projections for human trials, with allegations of animal suffering and ethical concerns regarding the technology.
U.S. Representative Earl Blumenauer has raised concerns about the FDA's oversight of Neuralink, questioning the agency's inspection processes and the company's safety lapses.
Neuralink's first human patient, Nolan Arbaugh, has been able to control a PC with his thoughts, showcasing the potential benefits of the technology despite the controversies.

One America News Network